Eos

What Eos does

Eos Advisory LLP is an FCA-regulated, St Andrews-based investment firm founded in 2014 that specialises in early-stage science and technology companies across the UK, deploying capital through a three-vehicle platform: a member-driven Angel Syndicate (minimum £5k per investment, accounting for c. 13% of investments per annum), an Eos-managed Innovation Fund (annual Q4 close, £25k minimum, typical £100k-£500k tickets, 5-8 deals per year across separate vintages) and Venture Partners (ad-hoc growth and Series A+ co-investments, £25k minimum, £100k-£1M+ per deal). The firm's portfolio, comprising more than twenty companies, is split between quality of life (disease diagnostics, prevention and treatment, food and water security) and environmental sustainability (clean energy, sustainable infrastructure, pollution), and includes Scottish university spinouts such as Dxcover (spectroscopic liquid biopsy with AI), Bioliberty (soft robotics rehabilitation, with US expansion funded by a March 2026 Series A) and Nami Surgical (ultrasonic scalpels for robotic-assisted surgery), as well as Bristol-based EnsiliTech and Scarlet Therapeutics.

Eos is FCA-authorised (reference 980583) and offers S/EIS UK tax relief on relevant investments, working in long-term partnerships with family offices, individuals, companies and institutional investors, most notably via a £10 million commitment from British Business Investments in June 2023. The firm's go-to-market is direct and relationship-driven, supported by a content-led website, an Angel Syndicate community that meets virtually monthly and in-person quarterly, and co-marketing partnerships with UKBAA, EISA and the British Business Bank. Investment Committee and partner composition includes founders, scientists, industry leaders and government advisors, including Managing Partner Andrew McNeill, Partner Chris Brinsmead, Director of Portfolio Anne Muir, Investment Director Rob Halliday, and Investment Committee members Rick Clark, Andrew Durkie and Ana Stewart.

Name

Eos

Legal name

Eos Advisory LLP

Website

https://eos-advisory.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Eos Advisory LLP is an FCA-regulated, St Andrews-based investment firm founded in 2014 that deploys seed and growth capital into UK science and technology companies via an Angel Syndicate, Innovation Fund and Venture Partners platform, serving family offices, HNW individuals and institutional investors alongside British Business Investments.

Ownership category

akta.pro rank

Product category

Venture Capital / Impact Investment Management

NAICS

Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Open-End Investment Funds (52591), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)

akta.pro industry

PRIMARYFSANAJAI

Healthcare Access & Life Sciences Impact Funds

Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds

SECONDARYFSANAJAN

SDG / Thematic Sustainable Investment Funds

Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds

SECONDARYFSAAAJAK

Multi-Asset ESG / Sustainable Allocation Strategies

Financial & Insurance/Asset & Wealth Management/Asset Management — Multi-Asset & Balanced

SECONDARYFSAAAIAM

Sustainable/ESG Equity (Active)

Financial & Insurance/Asset & Wealth Management/Asset Management — Equity (Active)

Keywords

• Venture capital investing
• Seed stage funding
• Angel syndicate management
• Impact investment firm
• Science technology investing

Headquarters

HQ city

Saint Andrews

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Fund management & investment returns: Eos Advisory generates revenue via managed and discretionary investment vehicles (Innovation Fund and Venture Partners) that deploy capital into early-stage science & technology companies. Returns derive from capital appreciation of equity investments held in portfolio companies, plus carried interest/management economics typical of an FCA-regulated investment manager.
2. Angel Syndicate arrangement & co-investment services: Eos arranges and administers an Angel Syndicate where members make investment decisions and commit equity capital alongside Eos-managed funds, with Eos providing deal sourcing, structuring and ongoing portfolio support.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Eos Advisory LLP is an FCA-regulated impact investment firm that deploys patient early-stage capital into UK science and technology companies through three complementary vehicles: an Angel Syndicate (member-driven, £5k minimum per investment), an Innovation Fund (Eos-managed seed investments with annual Q4 close, £25k minimum, £100k–£500k typical, 5–8 investments per year), and a Venture Partners programme (growth / Series A+ co-investment, £25k minimum, £100k–£1M+ typical). The portfolio is concentrated in quality of life (disease diagnostics, prevention and treatment, food and water security) and environmental sustainability (clean energy, sustainable infrastructure, pollution).

Product overview

Eos Advisory LLP operates a multi-vehicle investment platform rather than a single unified product: its offering is split across three complementary funding models — the Angel Syndicate (member-driven seed investing), the Innovation Fund (Eos-managed seed-stage fund), and Venture Partners (growth / Series A+ co-investments) — which together deploy early-stage patient capital into science and technology companies focused on quality of life and environmental sustainability. This investment platform is delivered alongside an Eos portfolio of seed- and growth-stage investee companies (e.g., Bioliberty, Dxcover, Laverock Therapeutics, Naturbeads, Penhros Bio, Chemify, Nami Surgical, Neupulse, EnsiliTech, Scarlet Therapeutics, Carcinotech, Biotangents, CamGene Therapeutics, Concinnity Genetics, Cumulus Oncology, Enough, GM Flow, ILC Therapeutics, Novosound, Novel Technologies / Silbac, and Wobble Genomics), offering S/EIS UK tax relief for relevant investors when available and long-term partnerships with family offices, individuals, companies, and institutional investors.

Differentiator

Problem solved

Functional benefit

Products and services

• Angel Syndicate

Quantifiable outcome

• British Business Investments committed up to £10 million to support Eos's early-stage science & technology investment activity across the UK
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core.

• UKBAA (UK Business Angels Association)coreStrategic or Co-development PartnerListed as a UKBAA member on the Eos Advisory homepage; partner logo linked to ukbaa.org.uk membership page.
• EISA (Enterprise Investment Scheme Association)coreStrategic or Co-development PartnerListed as a partner on the Eos Advisory homepage; partner logo linked to eisa.org.uk. Eos offers S/EIS UK tax relief for relevant investors when available, indicating alignment with EISA's mission.
• British Business BankcoreStrategic or Co-development PartnerPartner logo displayed on the Eos Advisory homepage, linked to bbinv.co.uk; supports the wider UK SME investment ecosystem in which Eos operates.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Archangels: Archangels is Scotland's longest-running angel investment syndicate, investing early-stage capital into Scottish technology and life sciences companies. It is directly comparable to Eos as a fellow Scottish early-stage specialist and was a co-investor with Eos in the Bioliberty Series A.
• Mercia Asset Management: Mercia is a UK regional venture capital and asset manager running EIS funds and university-connected vehicles across the Midlands and North of England. It is directly comparable to Eos as a UK regional seed/growth specialist and co-invested via its managed Midlands Engine Investment Fund II in the Neupulse round alongside Eos.
• Cambridge Innovation Capital: CIC is a Cambridge-based venture investor specialising in deep-tech and life-sciences spinouts from the University of Cambridge. It is directly comparable to Eos as a UK knowledge-intensive science and technology specialist at seed-to-growth stage.
• Parkwalk Advisors: Parkwalk is a UK investment manager specialising in university spinout and technology transfer opportunities, with EIS-eligible funds. It is directly comparable to Eos in focus on knowledge-intensive UK spinouts and use of S/EIS structures for HNW investors.
• Maven Capital Partners: Maven is a UK fund manager operating regional venture and growth funds including the Investment Fund for Scotland. It is directly comparable to Eos as a UK regional investor with managed seed/growth funds and was a co-investor with Eos in the Nami Surgical round.

Broad incumbents

• IP Group: IP Group is a listed UK IP commercialisation group that partners with universities to build deep-tech companies from research. It is a broader incumbent in the same university-spinout deep-tech niche that Eos targets, with a wider portfolio and public-market capital base.
• Octopus Ventures: Octopus Ventures is one of the largest UK VCs, backing science-, health- and deep-tech companies from seed to growth via funds such as Octopus Titan VCT. It is a broader incumbent in the same UK deep-tech seed-to-growth space Eos serves.
• Albion Capital: Albion Capital is a London-based investment manager with VCT/EIS funds backing UK growth-stage and technology companies. Comparable as a broader incumbent offering S/EIS-eligible structures to HNW investors, similar to Eos's Innovation Fund and Angel Syndicate vehicles.

Regional players

• Scottish Enterprise: Scottish Enterprise is Scotland's national economic development agency providing equity co-investment and grant funding to Scottish startups, including co-investing in Nami Surgical with Eos. Comparable as a regional institutional investor in Scottish science and technology companies.
• Scottish National Investment Bank: Scottish National Investment Bank is Scotland's development investment bank providing patient capital into Scottish companies. Comparable as a regional institutional investor in Scottish growth-stage companies and led the Bioliberty Series A that Eos participated in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eos-advisory

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries20 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments35 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eos